Loading…
Loading…


H1 results showed 16% sales growth, a 44% net profit increase, and EBITDA margin expansion to 34.8%, driven by higher asset utilization and segment outperformance. Integrated Biologics, Advanced Synthesis, and Specialized Modalities each delivered double-digit growth. Management raised its 2026 CORE EBITDA margin outlook to 33–34% while maintaining 11–12% sales growth guidance. Our buy rating is confirmed.

Lonza Group AG (LZAGY) Q1 2026 Earnings Call Transcript
No recent filings indexed.